menu
    • menu

    Company profile for Aerami Therapeutics

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    Smithfield BioScience transforms bioproducts into trusted, life-saving therapies through safe, reliable U.S.-based manufacturing.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    SWATI - Transforming science into solutions with 60+ years of expertise, global accreditations, and pioneering biotech innovation.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Aerami Therapeutics is developing a new generation of inhaled therapies for the treatment of severe respiratory and chronic diseases. Our platform is designed to overcome the limitations of injectable, oral, and other inhaled formulation technologies for managing severe respiratory and chronic diseases. Ultimately, our aim is to improve treatment efficacy and improve patient lives.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Aerami TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    2520 Meridian Parkway Suite 400 Durham, North Carolina 27713
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://aerami.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/aeramitx/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/AeramiTx

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Aerami Presents AER-901 Lung Deposition Modeling At ATS 2024
    Aerami Presents AER-901 Lung Deposition Modeling At ATS 2024

    20 May 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/05/20/2885171/0/en/Aerami-Therapeutics-Presents-New-Lung-Deposition-Modeling-Data-For-AER-901-in-Pulmonary-Hypertension-at-the-American-Thoracic-Society-2024-International-Conference.html

    GLOBENEWSWIRE
    20 May 2024
    Share Share
    Aerami AER-901 Lung Data At ATS 2024
    Aerami AER-901 Lung Data At ATS 2024

    08 May 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/05/08/2877813/0/en/Aerami-Therapeutics-to-Present-New-Lung-Deposition-Modeling-Data-for-AER-901-in-Development-for-Pulmonary-Hypertension-at-the-American-Thoracic-Society-2024-International-Conferenc.html

    GLOBENEWSWIRE
    08 May 2024
    Share Share
    Aerami to Present Data Supporting AER-901 Dosing Regimen at CHEST 2023
    Aerami to Present Data Supporting AER-901 Dosing Regimen at CHEST 2023

    05 Oct 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/10/05/2755336/0/en/Aerami-Therapeutics-to-Present-Data-Supporting-AER-901-Dosing-Regimen-at-CHEST-2023.html

    GLOBENEWSWIRE
    05 Oct 2023
    Share Share
    Aerami Announces Presentation of Phase 1 Trial Data for Lead Program AER-901
    Aerami Announces Presentation of Phase 1 Trial Data for Lead Program AER-901

    12 Sep 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/09/12/2741811/0/en/Aerami-Therapeutics-Announces-Presentation-of-Phase-1-Clinical-Trial-Data-for-Lead-Program-AER-901-at-the-2023-European-Respiratory-Society-ERS-International-Congress.html

    GLOBENEWSWIRE
    12 Sep 2023
    Share Share
    Aerami Therapeutics Expands Management Team
    Aerami Therapeutics Expands Management Team

    02 Jun 2023

    // CONTRACT PHARMA

    https://www.contractpharma.com/contents/view_breaking-news/2023-06-02/aerami-therapeutics-expands-management-team/?widget=listSection

    CONTRACT PHARMA
    02 Jun 2023
    Share Share
    Aerami Therapeutics Appoints Joshua Ziel as COO and Interim CEO
    Aerami Therapeutics Appoints Joshua Ziel as COO and Interim CEO

    01 Jun 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/06/01/2680278/0/en/Aerami-Therapeutics-Appoints-Joshua-Ziel-as-COO-and-Interim-CEO-and-Expands-Management-Team-as-Lead-Asset-AER-901-inhaled-imatinib-Advances-Toward-Phase-2-in-Pulmonary-Hypertension.html

    GLOBENEWSWIRE
    01 Jun 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search